For decades, millions of women have walked into clinics, described a complex web of physical and emotional symptoms, and walked out with a diagnosis of polycystic ovary syndrome (PCOS). This condition affects an estimated 170 million women globally during their reproductive years. It is one of the most common endocrine disorders in women, affecting one in eight globally. Yet, the name we have used for it is fundamentally flawed.

The term “PCOS” implies a localized, gynecological issue. It tells patients and practitioners alike that the root of the problem lies in pathological ovarian cysts. The reality, however, is that pathological ovarian cysts are not a feature of the condition, making the name a historical misnomer.

In a landmark step forward for women’s health, the medical community is officially changing the name. Following an unprecedented, rigorous global consensus process, PCOS has been renamed to polyendocrine metabolic ovarian syndrome (PMOS). This is not merely a semantic update; it is a clinical paradigm shift designed to correct widespread inaccuracies, improve patient outcomes, and validate the lived experiences of millions of women.

The harm of a misleading name

Words in medicine carry weight. The nomenclature of a disease dictates how it is researched, how it is coded in health systems, how physicians approach treatment, and, crucially, how patients understand their own bodies.

The term “polycystic ovary” has long been recognized as inaccurate and potentially harmful. The so-called “cysts” seen on an ultrasound are actually small, arrested antral follicles resulting from disordered folliculogenesis. By hyper-focusing on the ovaries, the traditional PCOS label obscures the diverse endocrine, metabolic, psychological, and dermatological features that define the disorder.

This inaccuracy has real-world consequences. Up to 70 percent of affected individuals remain undiagnosed, a delay heavily influenced by the confusion surrounding the condition’s defining features.

Furthermore, a name rooted entirely in reproductive function can reinforce cultural stigma, particularly in societies where immense social value is placed on fertility. Many patients report profound distress and dissatisfaction with their care, stemming from the communication breakdown caused by this misleading label.

The global consensus for change

Changing the name of a globally recognized syndrome is a monumental task. Previous efforts to rename the condition repeatedly stalled due to a lack of coordinated global consensus and alignment between patient advocacy groups. However, building on a clear mandate for change, a rigorous, multistep global consensus process was launched.

This initiative was governed by 56 leading academic, clinical, and patient organizations across the world. The process utilized iterative global surveys, gathering responses from over 14,360 people with the condition and multidisciplinary health professionals.

The guiding principles for the new name were clear: It had to prioritize scientific and medical accuracy, ensure clarity and ease of communication, avoid stigma (particularly terms directly linked to reproduction or fertility), and be culturally appropriate across diverse linguistic contexts. The consensus clearly favored an evolutionary approach, an accurate name that retained some similarity to the well-known “PCOS” acronym to ensure feasibility of implementation.

Deconstructing PMOS: a multisystem reality

The consensus arrived at polyendocrine metabolic ovarian syndrome (PMOS). This new name accurately reflects the condition’s multisystem pathophysiology by breaking down into three core pillars.

1. Polyendocrine

PMOS encompasses multiple interacting endocrine abnormalities, rather than an isolated ovarian disorder. The condition is driven by polygenic origins across neuroendocrine, metabolic, and reproductive pathways. A defining feature is hyperandrogenism, where elevated ovarian and adrenal androgens contribute to clinical symptoms like hirsutism, acne, and alopecia. By using the term “polyendocrine,” the medical community acknowledges that this is a system-wide hormonal disruption.

2. Metabolic

The inclusion of “metabolic” in the name is arguably the most critical clinical update. Metabolic abnormalities underpin PMOS from genetic origins through to clinical manifestations. Insulin resistance and compensatory hyperinsulinemia are present in roughly 85 percent of affected individuals, including 75 percent of lean women with the condition. This metabolic dysfunction amplifies androgen secretion and significantly increases cardiometabolic risks. Women with PMOS face increased rates of impaired glucose tolerance, type 2 diabetes, hypertension, and cardiovascular disease. By explicitly naming the metabolic component, the new terminology demands that clinicians look beyond reproductive years and actively manage long-term systemic health risks.

3. Ovarian

While moving away from the word “cyst,” it was vital to retain the ovarian connection. Ovarian dysfunction is a defining feature of PMOS. Neuroendocrine abnormalities disrupt ovarian steroidogenesis, impairing follicular maturation and leading to ovulatory dysfunction, menstrual irregularity, and infertility. The term “ovarian” accurately captures this without the pathological inaccuracy of the old name.

The road ahead: implementation and impact

A name change of this magnitude requires a carefully orchestrated global rollout. A co-designed global implementation strategy is already underway. This includes:

• A managed transition: A 3-year transition period is planned to monitor, evaluate, and support the shift in clinical, research, and policy environments.
• Health system integration: The new terminology will be incorporated into electronic health records and medical coding systems.
• Global policy alignment: Formal engagement with international bodies, including the World Health Organization (WHO), is underway to progress integration into disease classification systems like the International Classification of Diseases (ICD).
• Clinical guidelines: PMOS will be fully integrated into the next update of the International Guideline in 2028, which is currently utilized in 195 countries.

Conclusion

The transition from PCOS to PMOS is a testament to the power of patient advocacy and scientific evolution. For too long, patients have navigated a health care system using a map that did not match the territory of their own bodies.

Polyendocrine metabolic ovarian syndrome is more than just a new label; it is a clinical recalibration. It paves the way for earlier diagnoses, cohesive multidisciplinary care, targeted research funding, and, most importantly, a more empathetic and accurate understanding of women’s health.

As health care professionals, embracing this terminology is our first step toward providing the comprehensive, systemic care that these patients have always deserved.

Sathya Narayanan is a pharmacist in India.